Anti-Mouse MHC Class I (H-2Kk, H-2Dk) Antibody (15-3-1S (HB-13)) 

Anti-Mouse MHC Class I (H-2Kk, H-2Dk) Antibody (15-3-1S (HB-13)) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse MHC Class I. Anti-Mouse MHC Class I (H-2Kk, H-2Dk) Antibody (15-3-1S (HB-13)) reacts with the mouse H-2Kk and H-2Dk MHC class I alloantigens. Anti-Mouse MHC Class I (H-2Kk, H-2Dk) Antibody (15-3-1S (HB-13)) can be used for immunology research^[1].

Mouse IgG2a kappa

Mouse IgG2a kappa, Isotype Control

Mouse

The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Mouse MHC Class I (H-2Kk, H-2Dk) Antibody (15-3-1S (HB-13)) (30 μg, i.p., twice a week) induces chronic allograft vasculopathy in B6.RAG1−/−C3−/− mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

in vivo administration; Flow cytometry

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

150 kDa

[Anti-Mouse MHC Class I (H-2Kk, H-2Dk) Antibody (15-3-1S (HB-13))]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Hirohashi T, et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant. 2012 Feb;12(2):313-21.  [Content Brief]